Azitra (AZTR) Non-Current Assets (2022 - 2026)
Azitra (AZTR) posted Non-Current Assets of $1.4 million for Q1 2026, down 31.87% on a QoQ basis from $2.0 million in Q4 2025, and down 32.89% year-over-year from $2.0 million in Q1 2025.
Azitra (AZTR) Non-Current Assets (2022 - 2026) Analysis & Trends
Azitra's Non-Current Assets history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- Quarterly Non-Current Assets fell 32.89% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 14.19% YoY) and the FY2025 annual result came in at $2.0 million, down 5.84% from the prior year.
- Non-Current Assets was $1.4 million for Q1 2026 at Azitra, down from $2.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.0 million in Q4 2022 and bottomed at $1.4 million in Q1 2026.
- A 5-year average of $2.3 million and a median of $2.2 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets retreated 3.38% — and 2026, when it sank 32.89%.
- Azitra's Non-Current Assets stood at $3.0 million in 2022, then retreated by 14.9% to $2.6 million in 2023, then declined by 17.42% to $2.1 million in 2024, then slipped by 5.84% to $2.0 million in 2025, then slumped by 31.87% to $1.4 million in 2026.
- Business Quant data shows AZTR's Non-Current Assets at $1.4 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | 5.70 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 30.30 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 1.95 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 14.75 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 22.66 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | 289.41 Mn |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 1.96 Bn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 910.24 Mn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 285.82 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 2.54 Mn |
| Dec 31, 2023 | 2.58 Mn |
| Sep 30, 2023 | 2.63 Mn |
| Jun 30, 2023 | 2.99 Mn |
| Dec 31, 2022 | 3.03 Mn |